This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
== Discovery == Factor XIII Deficiency is also known as Laki–Lorand factor, after Kalman Laki and Laszlo Lorand, the scientists who first proposed its existence in 1948. A 2005 conference recommended standardization of nomenclature.
=== Gibbs–Donnan effect === In ion exchange chromatography, the Gibbs–Donnan effect is observed when the pH of the applied buffer and the ion exchanger differ, even up to one pH unit. For example, in anion-exchange columns, the ion exchangers repeal protons so the pH of the buffer near the column differs is higher than the rest of the solvent. As a result, an experimenter has to be careful that the protein(s) of interest is stable and properly charged in the "actual" pH. This effect comes as a result of two similarly charged particles, one from the resin and one from the solution, failing to distribute properly between the two sides; there is a selective uptake of one ion over another. For example, in a sulphonated polystyrene resin, a cation exchange resin, the chlorine ion of a hydrochloric acid buffer should equilibrate into the resin. However, since the concentration of the sulphonic acid in the resin is high, the hydrogen of HCl has no tendency to enter the column. This, combined with the need of electroneutrality, leads to a minimum amount of hydrogen and chlorine entering the resin.
The now elderly McCormick reunites with the also elderly Helen and asks her to marry him; she happily accepts, proving that true love does indeed last forever. McCormick introduces Nat to Helen, and the film ends with the three joining hands and going for a seaside stroll together.
=== Regulation of extracellular amyloid β-protein === Reports of IDE localized to the cytosol and peroxisomes have raised concerns regarding how the protease could degrade endogenous Aβ. Several studies have detected insulin-degrading activity in the conditioned media of cultured cells, suggesting the permeability of the cell membrane and thus possible release of IDE from leaky cells. Qiu and colleagues revealed the presence of IDE in the extracellular media using antibodies to the enzyme. They also quantified levels of Aβ-degrading activity using elution from column chromatography. Correlating the presence of IDE and Aβ-degrading activity in the conditioning medium confirmed that leaky membranes are responsible for extracellular IDE activity. However, other reports have indicated that it is released via exosomes.
They have a similar consistency and, in their raw form, have a similar texture but a sweeter, nuttier flavor. When raw and sliced thinly, they are fit for a salad. Their inulin form of carbohydrates give the tubers a tendency to become soft and mushy if boiled, but they retain their texture better when steamed. The inulin cannot be broken down by the human digestive system but bacteria metabolize it in the colon. This can cause flatulence and, in some cases, gastric pain. John Gerard's Herbal, printed in 1621, quotes the English botanist John Goodyer on Jerusalem artichokes:
Sources: en.wikipedia.org
== Research tools == Enzymes and receptors are often activated or inhibited by endogenous protein, but can be also inhibited by endogenous or exogenous small molecule inhibitors or activators, which can bind to the active site or on the allosteric site. An example is the teratogen and carcinogen phorbol 12-myristate 13-acetate, which is a plant terpene that activates protein kinase C, which promotes cancer, making it a useful investigative tool. There is also interest in creating small molecule artificial transcription factors to regulate gene expression, examples include wrenchnolol (a wrench shaped molecule). Binding of ligand can be characterised using a variety of analytical techniques such as surface plasmon resonance, microscale thermophoresis or dual polarisation interferometry to quantify the reaction affinities and kinetic properties and also any induced conformational changes.
== Endocrine functions of skeletal muscle == Under different physiological conditions, subsets of 654 different proteins as well as lipids, amino acids, metabolites and small RNAs occur in the secretome of skeletal muscles. Skeletal muscle is identified as an endocrine organ due to its secretion of cytokines and other peptides produced by skeletal muscle as signaling molecules. Iizuka et al., indicated that skeletal muscle is an endocrine organ because it "synthesizes and secretes multiple factors, and these muscle derived-factors exert beneficial effects on peripheral and remote organs." The altered secretomes after endurance training or resistance training as well as the secretome of sedentary muscle appear to have many effects on distant tissues. A study in Canada tested the effect of muscle mass on mental functions during aging. An expectation of the study was that the endocrine components of the secretome specific to skeletal muscle could protect cognitive functions. The skeletal muscle mass of arms and legs of 8,279 Canadians over the age of 65 and in average health was measured at baseline and after three years. Of these individuals, 1,605 participants (19.4%) were considered to have a low skeletal muscle mass at baseline, with less than 7.30 kg/m2 for males, and less than 5.42 kg/m2 for females (levels defined as sarcopenia in Canada). Executive mental function, memory and psychomotor speed were each measured at baseline and after three years.
Einsteinium is a synthetic chemical element; it has symbol Es and atomic number 99 and is a member of the actinide series and the seventh transuranium element. Einsteinium was discovered as a component of the debris of the first hydrogen bomb explosion in 1952. Its most common isotope, einsteinium-253 (253Es; half-life 20.47 days), is produced artificially from decay of californium-253 in a few dedicated high-power nuclear reactors with a total yield on the order of one milligram per year. The reactor synthesis is followed by a complex process of separating einsteinium-253 from other actinides and products of their decay. Other isotopes are synthesized in various laboratories, but in much smaller amounts, by bombarding heavy actinide elements with light ions. Due to the small amounts of einsteinium produced and the short half-life of its most common isotope, there are no practical applications for it except basic scientific research. In particular, einsteinium was used to synthesize, for the first time, 17 atoms of the new element mendelevium in 1955. Einsteinium is a soft, silvery, paramagnetic metal. Its chemistry is typical of the late actinides, with a preponderance of the +3 oxidation state; the +2 oxidation state is also accessible, especially in solids. The high radioactivity of 253Es produces a visible glow and rapidly damages its crystalline metal lattice, with released heat of about 1,000 watts per gram. Studying its properties is difficult due to 253Es's decay to berkelium-249 and then californium-249 at a rate of about 3% per day.
== Toxic analogues == Several non-proteinogenic amino acids are toxic due to their ability to mimic certain properties of proteinogenic amino acids, such as thialysine. Some non-proteinogenic amino acids are neurotoxic by mimicking amino acids used as neurotransmitters (that is, not for protein biosynthesis), including quisqualic acid, canavanine, caramboxin and azetidine-2-carboxylic acid. Cephalosporin C has an α-aminoadipic acid (homoglutamate) backbone that is amidated with a cephalosporin moiety. Penicillamine is a therapeutic amino acid, whose mode of action is unknown.
Within a year he was backtracking, announcing that sharia was inappropriate for the Jamahiriya because it guaranteed the protection of private property, contravening The Green Book's socialism. His emphasis on placing his own work on a par with the Qur'an led conservative clerics to accuse him of shirk, furthering their opposition to his regime. In July 1977, a border war broke out with Egypt, in which the Egyptians defeated Libya despite their technological inferiority. The conflict lasted one week before both sides agreed to sign a peace treaty that was brokered by several Arab states. Both Egypt and Sudan had aligned themselves with the US, and this pushed Libya into a strategic, although not political, alignment with the Soviet Union. In recognition of the growing commercial relationship between Libya and the Soviets, Gaddafi was invited to visit Moscow in December 1976; there, he entered talks with Leonid Brezhnev. In August 1977, he visited Yugoslavia, where he met its leader Josip Broz Tito, with whom he had a much warmer relationship. He also enjoyed a warm relationship with Romanian leader Nicolae Ceaușescu. According to Romanian spy chief Ion Mihai Pacepa, Gaddafi once exclaimed to Ceaușescu, "My brother! You are my brother for the rest of my life!" After Pacepa defected to the US in July 1978, Gaddafi and Yasser Arafat contributed $1 million each to Ceaușescu's $4 million bounty on Pacepa.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.